JP2011530513A5 - - Google Patents

Download PDF

Info

Publication number
JP2011530513A5
JP2011530513A5 JP2011522113A JP2011522113A JP2011530513A5 JP 2011530513 A5 JP2011530513 A5 JP 2011530513A5 JP 2011522113 A JP2011522113 A JP 2011522113A JP 2011522113 A JP2011522113 A JP 2011522113A JP 2011530513 A5 JP2011530513 A5 JP 2011530513A5
Authority
JP
Japan
Prior art keywords
phenyl
methyl
pyrido
dihydro
phthalazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011522113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011530513A (ja
JP5984389B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/051879 external-priority patent/WO2010017055A2/en
Publication of JP2011530513A publication Critical patent/JP2011530513A/ja
Publication of JP2011530513A5 publication Critical patent/JP2011530513A5/ja
Application granted granted Critical
Publication of JP5984389B2 publication Critical patent/JP5984389B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011522113A 2008-08-06 2009-07-27 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤 Active JP5984389B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8668708P 2008-08-06 2008-08-06
US61/086,687 2008-08-06
US15103609P 2009-02-09 2009-02-09
US61/151,036 2009-02-09
US17308809P 2009-04-27 2009-04-27
US61/173,088 2009-04-27
PCT/US2009/051879 WO2010017055A2 (en) 2008-08-06 2009-07-27 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015093417A Division JP2015157843A (ja) 2008-08-06 2015-04-30 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤

Publications (3)

Publication Number Publication Date
JP2011530513A JP2011530513A (ja) 2011-12-22
JP2011530513A5 true JP2011530513A5 (enExample) 2012-09-13
JP5984389B2 JP5984389B2 (ja) 2016-09-06

Family

ID=41129519

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011522113A Active JP5984389B2 (ja) 2008-08-06 2009-07-27 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤
JP2015093417A Pending JP2015157843A (ja) 2008-08-06 2015-04-30 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤
JP2017145036A Pending JP2018012698A (ja) 2008-08-06 2017-07-27 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015093417A Pending JP2015157843A (ja) 2008-08-06 2015-04-30 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤
JP2017145036A Pending JP2018012698A (ja) 2008-08-06 2017-07-27 ポリ(adp−リボース)ポリメラーゼ(parp)のジヒドロピリドフタラジノン阻害剤

Country Status (31)

Country Link
US (7) US8012976B2 (enExample)
EP (3) EP3241832A1 (enExample)
JP (3) JP5984389B2 (enExample)
KR (1) KR101846029B1 (enExample)
CN (3) CN102171214B (enExample)
AR (1) AR072970A1 (enExample)
AU (1) AU2009279944B2 (enExample)
BR (1) BRPI0917119B1 (enExample)
CA (1) CA2732797C (enExample)
CY (3) CY1115022T1 (enExample)
DK (2) DK2767537T3 (enExample)
ES (2) ES2466565T3 (enExample)
FR (1) FR19C1071I2 (enExample)
GB (1) GB2462361A (enExample)
HR (1) HRP20170982T1 (enExample)
HU (2) HUE035295T2 (enExample)
IL (1) IL211070A (enExample)
LT (2) LT2767537T (enExample)
LU (1) LUC00140I2 (enExample)
MX (1) MX2011001328A (enExample)
NL (1) NL301021I2 (enExample)
NO (1) NO2019042I1 (enExample)
NZ (1) NZ591166A (enExample)
PL (2) PL2767537T3 (enExample)
PT (2) PT2326650E (enExample)
SG (2) SG193842A1 (enExample)
SI (2) SI2767537T1 (enExample)
SM (1) SMT201700312T1 (enExample)
TW (2) TW201422617A (enExample)
WO (1) WO2010017055A2 (enExample)
ZA (1) ZA201100897B (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193842A1 (en) 2008-08-06 2013-10-30 Biomarin Pharm Inc Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
MX2011006503A (es) 2008-12-19 2011-09-06 Vertex Pharma Derivados de pirazina utiles como inhibidores de la cinasa de atr.
US8541403B2 (en) * 2010-02-03 2013-09-24 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
PT2533640T (pt) * 2010-02-08 2017-01-03 Medivation Technologies Inc Processos de síntese de derivados de di-hidropiridoftalazinona
WO2011130661A1 (en) * 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
BR112013009117A2 (pt) 2010-10-21 2016-07-19 Biomarin Pharm Inc sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo.
WO2012166151A1 (en) * 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
CN106496173A (zh) 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
CA2850491C (en) 2011-09-30 2020-10-27 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with atr inhibiors
DK2797921T3 (en) 2011-12-31 2017-10-02 Beigene Ltd FUSED TETRA- OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARB INHIBITORS
EP2797919B1 (en) * 2011-12-31 2017-03-29 BeiGene, Ltd. Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
WO2013110058A2 (en) 2012-01-20 2013-07-25 Bacha Jeffrey Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
WO2013152298A1 (en) 2012-04-05 2013-10-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US9855261B2 (en) 2012-11-08 2018-01-02 Nippon Kayaku Kabushiki Kaisha Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same
MY191366A (en) 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN105764502A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群及其类似物及衍生物的治疗益处的组合方法
US20160280691A1 (en) 2013-11-07 2016-09-29 Biomarin Pharmaceutical Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
CN107155326B (zh) 2014-07-31 2021-03-05 麦迪韦逊科技有限公司 一种共形成体盐及其制备方法
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
EP3317277B1 (en) 2015-07-01 2021-01-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
NZ739876A (en) 2015-08-25 2022-09-30 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
CN110087730B (zh) * 2016-09-27 2023-03-28 百济神州(苏州)生物科技有限公司 使用包含parp抑制剂的组合产品治疗癌症
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN108210461A (zh) * 2016-12-16 2018-06-29 中国科学院上海药物研究所 一种Talazoparib药物组合物及其应用
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
CN107556312B (zh) * 2016-12-29 2020-04-10 广州丹康医药生物有限公司 具有parp抑制活性的新型稠环化合物、其制备方法和用途
CN107573341B (zh) * 2016-12-29 2020-08-14 广州丹康医药生物有限公司 作为parp抑制剂的新型稠环化合物、其制备方法和应用
CN110392687B (zh) 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
CN110650961B (zh) * 2017-05-08 2022-09-27 广州丹康医药生物有限公司 Parp抑制剂、其药物组合物、制备方法和应用
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
AU2018347331A1 (en) 2017-10-13 2020-04-09 Merck Patent Gmbh Combination of a PARP inhibitor and a PD-1 axis binding antagonist
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN108341792B (zh) * 2018-04-28 2021-09-17 苏州莱克施德药业有限公司 一种Volasertib中间体1-环丙基甲基哌嗪的制备方法
MX2020012066A (es) 2018-05-14 2021-04-28 Nuvation Bio Inc Compuestos anticancerígenos dirigidos a los receptores hormonales nucleares.
CN108676888B (zh) * 2018-07-12 2022-01-28 吉林大学 一种肺部恶性肿瘤易感性预测试剂盒及系统
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
WO2020095184A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combinations for treating cancer
CN114206864B (zh) 2019-05-14 2024-05-24 苏州四体康宸医药科技有限公司 喹唑啉-2.4-二酮衍生物作为parp抑制剂
MX2021013774A (es) 2019-05-14 2021-12-10 Nuvation Bio Inc Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法
JP2023517044A (ja) 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
IL302889A (en) 2020-11-13 2023-07-01 Pfizer Talazoparib soft gelatin capsule dosage form
MX2023006768A (es) 2020-12-07 2023-06-19 Pfizer Metodos de identificacion de un tumor sensible al tratamiento con talazoparib y metodos de tratamiento del mismo.
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
EP4313034A1 (en) 2021-03-24 2024-02-07 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
US20240279225A1 (en) * 2021-04-08 2024-08-22 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4089093A1 (en) * 2021-05-12 2022-11-16 Eberhard Karls Universität Tübingen Medizinische Fakultät Radiosynthesis of [18f] talazoparib
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
US20250346599A1 (en) * 2022-06-08 2025-11-13 Valo Health, Inc. Tricyclic phthalazinone parp inhibitors and methods of use
CN115572218B (zh) * 2022-08-29 2024-04-16 江阴勒森生物科技有限公司 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法
TWI883565B (zh) 2022-10-02 2025-05-11 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
TW202425976A (zh) 2022-12-17 2024-07-01 美商輝瑞大藥廠 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合
CN116283924B (zh) * 2023-01-16 2024-07-26 四川效佳科技有限公司 一种药用级纯度的苯甲酸利扎曲普坦的重结晶方法
WO2025210510A1 (en) 2024-04-04 2025-10-09 Pfizer Inc. Tmprss2-erg and rb1 as predictive biomarkers for treatment with a parp inhibitor

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106631A (en) * 1870-08-23 Improvement in seed-planter
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) * 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd 2−キノロン誘導体
US5328905A (en) 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
MX9701075A (es) 1994-08-12 1998-03-31 Myriad Genetics Inc Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
WO1996005308A1 (en) 1994-08-12 1996-02-22 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
GB9505538D0 (en) * 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
WO1999059975A1 (en) 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
AU2003211381B9 (en) 2002-02-19 2009-07-30 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
JPWO2004043959A1 (ja) 2002-11-12 2006-03-09 持田製薬株式会社 新規parp阻害剤
KR101146806B1 (ko) 2003-03-12 2012-05-22 메이브릿지 리미티드 프탈라지논 유도체
JP4824566B2 (ja) 2003-05-28 2011-11-30 エーザイ インコーポレーテッド Parpを阻害するための化合物、方法、および医薬組成物
BRPI0507498A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir ativação de receptores de mglur 5
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
CA2697246A1 (en) 2007-08-22 2009-02-26 4Sc Ag Indolopyridines as inhibitors of the kinesin spindle protein (eg5)
DK2209375T3 (da) * 2007-10-03 2014-10-06 Eisai Inc Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
CN101998959B (zh) 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
SG193842A1 (en) 2008-08-06 2013-10-30 Biomarin Pharm Inc Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
MX2011001563A (es) 2008-08-12 2011-03-04 Boehringer Ingelheim Int Procedimiento para la preparacion de compuestos de piperazina sustituidos con cloalquilo.
US8541403B2 (en) 2010-02-03 2013-09-24 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
PT2533640T (pt) * 2010-02-08 2017-01-03 Medivation Technologies Inc Processos de síntese de derivados de di-hidropiridoftalazinona
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
BR112013009117A2 (pt) 2010-10-21 2016-07-19 Biomarin Pharm Inc sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo.
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
US20160280691A1 (en) 2013-11-07 2016-09-29 Biomarin Pharmaceutical Inc. Triazole intermediates useful in the synthesis of protected n-alkyltriazolecarbaldehydes
CN107155326B (zh) 2014-07-31 2021-03-05 麦迪韦逊科技有限公司 一种共形成体盐及其制备方法

Similar Documents

Publication Publication Date Title
JP2011530513A5 (enExample)
JP2015157843A5 (enExample)
ES3021205T3 (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
EP3381896B1 (en) Biphenyl compound or salt thereof
JP7240784B2 (ja) 8,9-ジヒドロイミダゾール[1,2-a]ピリミド[5,4-e]ピリミジン-5(6H)-ケトン類化合物
WO2023066350A1 (zh) Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
US9844553B2 (en) Pyrazolopyridyl compounds as aldosterone synthase inhibitors
CN102171214B (zh) 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
US9260435B2 (en) Substituted imidazopyrazines as Akt kinase inhibitors
JP2013518892A5 (enExample)
JP2019504821A (ja) ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
US20240124422A1 (en) Mutant pi3k-alpha inhibitors and their use as pharmaceuticals
KR20240053612A (ko) Parp 억제제로서 치환된 삼환 화합물 및 이의 용도
CN114790209A (zh) 优化的联合用药及其治疗癌症和自身免疫疾病的用途
KR101739003B1 (ko) 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
EP4011885A1 (en) Oxo-pyridine fusion ring derivative and pharmaceutical composition comprising same
AU2014284013B2 (en) Five-membered heterocyclic pyridine compounds and preparation method and use thereof
US9370517B2 (en) Substituted pyrazolopyrimidines as Akt kinase inhibitors
WO2016165657A1 (zh) 激酶抑制剂的制备及应用
EP2920154B1 (en) Novel imidazol-piperidinyl derivatives as modulators of kinase activity
CN109020981A (zh) 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物
EP2934144B1 (en) Indazole compounds as aldosterone synthase inhibitors
US20240150362A1 (en) Substituted Pyrrolotriazines
CN106045967A (zh) 取代杂环化合物及其在药物上的应用
CN120826404A (zh) 取代的含氮三环类化合物作为parp抑制剂及其应用